US20040258701A1 - Microfluidized oil-in-water emulsions and vaccine compositions - Google Patents

Microfluidized oil-in-water emulsions and vaccine compositions Download PDF

Info

Publication number
US20040258701A1
US20040258701A1 US10/818,433 US81843304A US2004258701A1 US 20040258701 A1 US20040258701 A1 US 20040258701A1 US 81843304 A US81843304 A US 81843304A US 2004258701 A1 US2004258701 A1 US 2004258701A1
Authority
US
United States
Prior art keywords
oil
antigen
vaccine composition
emulsion
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/818,433
Other languages
English (en)
Inventor
Paul Dominowski
Pamela Klose
Richard Krebs
Ramasamy Mannan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis LLC
Original Assignee
Pfizer Products Inc
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33131921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040258701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc, Pfizer Inc filed Critical Pfizer Products Inc
Priority to US10/818,433 priority Critical patent/US20040258701A1/en
Assigned to PFIZER INC., PFIZER PRODUCTS, INC. reassignment PFIZER INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOMINOWSKI, PAUL J., KLOSE, PAMELA, MANNAN, RAMASAMY, KREBS, RICHARD L.
Publication of US20040258701A1 publication Critical patent/US20040258701A1/en
Priority to US12/650,715 priority patent/US8771727B2/en
Assigned to PFIZER INC. reassignment PFIZER INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PFIZER PRODUCTS INC.
Assigned to AH USA 42 LLC reassignment AH USA 42 LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PFIZER INC.
Assigned to PFIZER INC. reassignment PFIZER INC. CORRECTION BY DECLARATION OF INCORRECT NUMBERS RECORDED AT REEL 029041 FRAME 0099. Assignors: PFIZER INC.
Assigned to PFIZER INC. reassignment PFIZER INC. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 015738 FRAME 0224. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: DOMINOWSKI, PAUL J., KLOSE, PAMELA, MANNAN, RAMASAMY, KREBS, RICHARD L.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates generally to the field of vaccines and particularly, to adjuvant formulations for enhancing immune response in veterinary animals.
  • the invention relates to the use of a submicron oil-in-water emulsion as a vaccine adjuvant for enhancing the immunogenicity of antigens.
  • Submicron oil-in-water emulsion formulations, vaccine compositions containing an antigen incorporated into such emulsions, as well as methods of preparing the emulsions and vaccines, are provided by the present invention.
  • Bacterial, viral, parasitic and mycoplasma infections are wide spread in the veterinary animals such as cattle, swine and companion animal. Diseases caused by these infectious agents are often resistant to antimicrobial pharmaceutical therapy, leaving no effective means of treatment. Consequently, a vaccinology approach is increasingly used to control the infectious disease in the veterinary animals.
  • a whole infectious pathogen can be made suitable for use in a vaccine formulation after chemical inactivation or appropriate genetic manipulation.
  • a protein subunit of the pathogen can be expressed in a recombinant expression system and purified for use in a vaccine formulation.
  • Adjuvant generally refers to any material that increases the humoral and/or cellular immune response to an antigen.
  • the traditional vaccines are composed of crude preparation of killed pathogenic microorganisms, and the impurities associated with the cultures of pathological microorganisms could act as adjuvant to enhance the immune response.
  • the immunity invoked by such antigens is poor and the addition of certain exogenous materials as adjvuant therefore becomes necessary.
  • synthetic and subunit vaccines are expensive to produce. Therefore, with the aid of adjuvant, a smaller dose of antigen may be required to stimulate the immune response, thereby saving the production cost of vaccines.
  • Adjuvants are known to act in a number of different ways to enhance the immune response. Many adjuvants modify the cytokine network associated with immune response. These immunomodulatory adjuvants can exert their effect even when they are not together with antigens. In general the immunomodulatory adjuvants cause a general up-regulation of certain cytokines and a concomitant down regulation of others leading to a cellular Th1 and/or a humoral Th2 response.
  • Some adjuvants have the ability to preserve the conformational integrity of an antigen so that the antigens can be efficiently presented to appropriate immune effector cells.
  • the vaccine would have an increased shelf-life such as that shown for immune stimulating complexes (ISCOMs). Ozel M.,et.al.; Quarternary Structure of the Immunestimmulating Complex (Iscom), J.of Ultrastruc. and Molec. Struc. Res. 102, 240-248 (1989).
  • FCA Freund's complete adjuvant
  • adjuvants can be grouped under two very broad categories, namely particulate adjvuants and non-particulate adjvuants.
  • Particulate adjuvants exist as microparticles.
  • the immunogen is either able to incorporate or associate with the microparticles.
  • Aluminum salts, water-in-oil emulsions, oil-in-water emulsions, immune stimulating complexes, liposomes, and nano- and microparticles are examples of particulate adjuvants.
  • the non-particulate adjuvants are generally immunomodulators and they are generally used in conjunction with particulate adjuvants.
  • Muramyl dipeptide an adjuvant-active component of a peptidoglycan extracted from Mycobacteria
  • non-ionic block copolymers Non-ionic block copolymers
  • Saponins a complex mixture of triterpenoids extracted from the bark of the Quillaja saponaria tree
  • Lipid A a disaccharide of glucosamine with two phosphate groups and five or six fatty acid chains generally C12 to C16 in length
  • cytokines a disaccharide of glucosamine with two phosphate groups and five or six fatty acid chains generally C12 to C16 in length
  • cytokines a disaccharide of glucosamine with two phosphate groups and five or six fatty acid chains generally C12 to C16 in length
  • cytokines a disaccharide of glucosamine with two phosphate groups and five or six fatty acid chains generally C12 to C16 in length
  • cytokines a disaccharide of gluco
  • FCA combines the immunomodualtory properties of Mycobacterium tuberculosis components along with the short-term depot effect of oil emulsions.
  • FCA Freund's Complete Adjuvant
  • FCA is excellent in inducing an antibody response, it causes severe pain, abscess formation, fever and granulomatous inflammation. To avoid these undesirable side reactions, Incomplete Freund's Adjuvant (IFA) was developed. IFA is similar to FCA in its composition except for the absence of mycobacterial components. IFA acts through depot formulation at the site of injection and slow release of the antigen with stimulation of antibody-producing cells.
  • Adjuvant 65 was safe and potent but exhibited less adjuvanticity than IFA. Nevertheless, the use of Adjvuant 65 was discontinued due to reactogenicity for man with certain lots of vaccine and reduction in adjuvanticity when a purified or synthetic emulsifier was used in place of Arlacel A.
  • U.S. Pat. Nos. 5,718,904 and 5,690,942 teach that the mineral oil in the oil-in-water emulsion can be replaced with metabolizable oil for the purpose of improving the safety profile.
  • the physical appearance of an emulsion is also an important commercial consideration. Physical appearance depends on the stability of the emulsion. Creaming, sedimentation and coalescence are indicators of the emulsion instability. Creaming occurs when oil and aqueous phases of the emulsion have different specific gravity. Creaming also occurs when the initial droplet size of the emulsion is large and the emulsion droplets are not having any Brownian motion. When the droplet size is large, there is a tendency for the interfacial rupture and the droplets coalesce into large particles. The stability of the emulsion is determined by a number of factors such as the nature and amount of emulsifier used, the size of the droplet size in the emulsion, and the difference in the density between the oil and water phase.
  • Emulsifiers promote stabilization of dispersed droplet by reducing the interfacial free energy and creating physical or electrostatic barriers to droplet coalescence.
  • Nonionic as well as ionic detergents have been used as emulsifiers.
  • Nonionic emulsifiers orient at the interface and produce relatively bulky structures, which leads to steric avoidance of the dispersed droplets.
  • Anionic or cationic emulsifiers induce formation of an electrical double layer by attracting counter ions; the double layer repulsive forces cause droplets to repel one another when they approach.
  • the stability of the emulsion can also be achieved through reducing the droplet size of the emulsion by mechanical means.
  • propeller mixers, turbine rotors, colloid mills, homogenizers, and sonicators have been used to manufacture emulsions.
  • Microfluidization is another way to increase the homogeneity of the droplet size in the emulsion. Microfluidization can produce an elegant, physically stable emulsion with consistent particle size in the submicron range.
  • the process of microfluidization allows terminal filtration which is a preferred way of ensuring the sterility of the final product.
  • submicron oil particles can pass from injection sites into the lymphatics and then to lymph nodes of the drainage chain, blood and spleen. This reduces the likelihood of establishing an oily depot at the injection site which may produce local inflammation and significant injection site reaction.
  • Microfluidizers are now commercially available. Emulsion formation occurs in a microfluidizer as two fluidized streams interact at high velocities within an interaction chamber.
  • the microfluidizer is air or nitrogen driven and can operate at internal pressures in the excess of 20,000 psi.
  • U.S. Pat. No. 4,908,154 teaches the use of microfluidizer for obtaining emulsions essentially free of any emulsifying agents.
  • SAF Syntax Adjuvant Formulation
  • Squalane is prepared by hydrogenation of squalene and is fully saturated. Both squalene and squalane can be metabolized and have a good record of toxicological studies. Squalene or squalane emulsions have been used in human cancer vaccines with mild side effects and a desirable efficacy. See, e.g., Anthony C. Allison, 1999, Squalene and Squalane emulsions as adjuvants, Methods 19:87-93.
  • U.S. Pat. No. 5,961,970 teaches yet another submicron oil-in-water emulsion to be used as a vaccine adjuvant.
  • the hydrophobic component is selected from the group consisting of a medium chain triglyceride oil, a vegetable oil and a mixture thereof.
  • the surfactant included in this emulsion can be a natural biologically compatible surfactant such as phospholipid (e.g., lecithin) or a pharmaceutically acceptable non-natural surfactant such as TWEEN-80.
  • This patent also teaches incorporating the antigen into the emulsion at the time the emulsion is formed, in contrast to mixing the antigen with the emulsion after the emulsion has been independently and extrinsically formed.
  • U.S. Pat. No. 5,084,269 teaches that an adjuvant formulation containing lecithin in combination with mineral oil causes a decrease in irritation within the host animal and simultaneously induces increased systemic immunity.
  • the adjuvant formulation resulting from U.S. Pat. 5,084,269 is commercially used in veterinary vaccines under the trade name AMPHIGEN®.
  • the AMPHIGEN® formulation is made up of micelles—oil droplets surrounded by lecithin. These micelles allow more whole cell antigens to attach than traditional oil-based adjuvants.
  • the AMPHIGEN®-based vaccine formulations contain a low oil content of 2.5 to 5% mineral oil, compared to other vaccine formulations containing oil adjuvants, which typically contain from 10% to 20% oil. Its low oil content makes this adjuvant-based vaccine formulation less irritating to tissues at the injection site, resulting in fewer lesions and less trim at slaughter.
  • the lecithin coating surrounding the oil droplets further reduces injection site reactions resulting in a vaccine that is both safe and efficacious.
  • the AMPHIGEN® formulation is used as an adjuvant in a number of veterinary vaccines and there is need to maintain the physical appearance of the vaccine product during short and long storage periods as well as at the time of reconstitution.
  • a lyophilized antigen is mixed with the pre-made adjuvant formulation just before the injection. This practice does not always ensure that there is a uniform distribution of the antigen within the oil-in-water emulsion and the appearance of the emulsion may not be desirable.
  • the homogenized emulsion can show phase separation. Therefore, there exists a need for a stable adjuvant formulation which does not show phase separation upon long shelf-life.
  • One way to prevent the phase separation is to reduce the droplet size and increase the particle homogeneity of the emulsion. While the process of microfluidization of metabolizable oil-based emulsion formulations has been documented, microfluidization of oil-in-water emulsions such as the AMPHIGEN® formulation has not yet been carried out.
  • microfluidization has been used to bring the size of lecithin-surrounded mineral oil droplets to submicron size.
  • microfluidization of vaccine formulations adjuvanted with an oil-in-water emulsion comprised of a mixture of lecithin and oil not only improves the physical appearance of the formulations, but also enhances the immunizing effects of the formulations.
  • Microfluidized formulations are also characterized by an improved safety profile.
  • the present invention provides submicron oil-in-water emulsion formulations useful as a vaccine adjuvant.
  • the submicron oil-in-water emulsions of the present invention are composed of a non-metabolizable oil, at least one surfactant, and an aqueous component, where the oil is dispersed in the aqueous component with an average oil droplet size in the submicron range.
  • a preferred non-metabolizable oil is light mineral oil.
  • Preferred surfactants include lecithin, TWEEN®-80 and SPAN®-80.
  • a preferred oil-in-water emulsion provided by the present invention is composed of an AMPHIGEN®formulation.
  • the oil-in-water emulsions of the present invention can include additional components that are appropriate and desirable, including preservatives, osmotic agents, bioadhesive molecules, and immunostimulatory molecules.
  • Preferred immunostimulatory molecules include, e.g., Quil A, cholesterol, GPI-0100, dimethyldioctadecylammonium bromide (DDA).
  • the present invention provides methods of preparing a submicron oil-in-water emulsion.
  • the various components of the emulsion including oil, one or more surfactants, an aqueous component and any other component appropriate for use in the emulsion, are mixed together.
  • the mixture is subjected to a primary emulsification process to form an oil-in-water emulsion, which is then passed through a microfluidizer to obtain an oil-in-water emulsion with droplets of less than 1 micron in diameter, preferably with a mean droplet size of less than 0.5 micron.
  • the present invention provides vaccine compositions which contain an antigen and a submicron oil-in-water emulsion described hereinabove.
  • the antigen is incorporated into the emulsion either extrinsically or intrinsically, preferably, intrinsically.
  • the antigen which can be included in the vaccine compositions of the present invention can be a bacterial, fungal, or viral antigen, or a combination thereof.
  • the antigen can take the form of an inactivated whole or partial cell or virus preparation, or the form of antigenic molecules obtained by conventional protein purification, genetic engineering techniques or chemical synthesis.
  • the present invention provides methods of preparing vaccine compositions containing an antigen or antigens combined with a submicron oil-in-water emulsion.
  • the antigen(s) can be combined either intrinsically (e.g., prior to microfluidization) or extrinsically (e.g., after microfluidization) with the components of the oil-in-water emulsion.
  • the antigen is combined with the components of the oil-in-water emulsion intrinsically.
  • the present invention provides vaccine compositions which contain a microencapsulated antigen and a submicron oil-in-water emulsion described hereinabove, where the microencapsulated antigen is combined with the emulsion extrinsically.
  • FIG. 1 depicts the process for the batch preparation of non-microfluidized vaccine compositions.
  • the various vaccine components are added to the addition vessel on the left and ultimately pumped into the blend vessel where the components are mixed together through simple mechanical means.
  • FIG. 2 depicts the process for preparation of microfluidized vaccine compositions containing intrinsically incorporated antigen.
  • the various vaccine components are added to the addition vessel and transferred to the pre-emulsion blending unit for mixing through simple mechanical means. Subsequently, the emulsion is passed through a microfluidizer and is collected in the post-microfluidization chamber.
  • FIG. 3 depicts the droplet size distribution of the non-microfluidized AMPHIGEN® formulation-based vaccine, the microfluidized AMPHIGEN® formulation-based vaccine, and the bench blend vaccine preparation.
  • FIG. 4 shows absence of phase separation in the microfluidized vaccine preparation.
  • FIG. 5 depicts a comparison of the stability of antigens intrinsically incorporated in microfluidized AMPHIGEN® formulation-based vaccine preparation (A907505) and three control, non-microfluidized AMPHIGEN®) formulation-based vaccine preparations (A904369, A904370, and A904371). All four vaccine preparations were stored at 4° C. for two years. At different points during the storage (0, 6, 12 or 24 months), all four formulations were used to vaccinate the three months old cows. Vaccination was done Day 0 and 21 with a 2 ml vaccine dose and the sera were collected two weeks post second vaccination. Neutralizing antibody titer for BVD Type II virus was determined in each of the serum samples. The data are presented as the geometric mean for 5 animals.
  • FIG. 6 shows least squares mean rectal temperature of cattle prior to and following administration of microfluidized and non-microfluidized vaccines.
  • T01 Placebo group—single dose
  • T02 Placebo group—Double dose
  • T03 Non-microfluidized formulation—Single Dose
  • T04 Non-microfluidized formulation—Double dose
  • T05 Microfluidized formulation—Single Dose
  • T06 Microfluidized formulation—Double dose.
  • FIG. 7 depicts least squares mean injection site reaction volumes observed in cattle following administration of non-microfluidized and microfluidized vaccine formulations.
  • T03 Non-microfluidized formulation—Single Dose
  • T04 Non-microfluidized formulation—Double dose
  • T05 Microfluidized formulation—Single Dose
  • T06 Microfluidized formulation—Double dose.
  • FIG. 8 depicts geometric mean IgG titers for recombinant PauA antigen from Streptococcus uberis after vaccination with the various vaccine formulations containing both recombinant PauA antigen and E. coli whole cell antigen.
  • FIG. 9 depicts geometric mean IgG titers for E. coli whole cell antigen from Streptococcus uberis after vaccination with the various vaccine formulations containing both recombinant PauA antigen and E. coli whole cell antigen.
  • FIGS. 10A and 10B depict the particle size distribution of a Microfluidized Amphigen formulation at initial production (FIG. 10A) and at 22 months post production (FIG. 10B).
  • microfluidization of vaccine formulations adjuvanted with an oil-in-water emulsion comprised of a mixture of lecithin and mineral oil not only improves the physical appearance of the vaccine formulations, but also enhances the immunizing effects of the vaccine formulations.
  • Microfluidized vaccine formulations are also characterized by an improved safety profile.
  • the present invention provides submicron oil-in-water emulsions useful as an adjuvant in vaccine compositions. Methods of making these submicron oil-in-water emulsions by using a microfluidizer are also provided. Furthermore, the present invention provides submicron vaccine compositions in which an antigen is combined with a submicron oil-in-water emulsion. Methods for making such vaccine compositions are also provided. The present invention further provides vaccine compositions containing microencapsulated antigens combined with a submicron oil-in-water emulsion and methods for making such vaccines.
  • the present invention provides submicron oil-in-water emulsion formulations useful as a vaccine adjuvant.
  • the submicron oil-in-water emulsions of the present invention enhance the immunogenicity of antigens in vaccine compositions, are safe for administration to animals and stable during storage.
  • the submicron oil-in-water emulsions of the present invention are composed of a non-metabolizable oil, at least one surfactant, and an aqueous component, where the oil is dispersed in the aqueous component with an average oil droplet size in the submicron range.
  • submicron is meant that the droplets are of a size of less than 1 ⁇ m (micron) and the average or mean oil droplet size is less than 1 ⁇ m.
  • the mean droplet size of the emulsion is less than 0.8 ⁇ m; more preferably, less than 0.5 ⁇ m; and even more preferably, less than 0.4 ⁇ m, or about 0.1-0.3 ⁇ m.
  • the “mean droplet size” is defined as the Volume Mean Diameter (VMD) particle size within a volume distribution of particle sizes.
  • VMD Volume Mean Diameter
  • non-metabolizable oil refers to oils that cannot be metabolized by the body of the animal subject to which the emulsion is administered.
  • animal and “animal subject” as used herein refer to all non-human animals, including cattle, sheep, and pigs, for example.
  • Non-metabolizable oils suitable for use in the emulsions of the present invention include alkanes, alkenes, alkynes, and their corresponding acids and alcohols, the ethers and esters thereof, and mixtures thereof.
  • the individual compounds of the oil are light hydrocarbon compounds, i.e., such components have 6 to 30 carbon atoms.
  • the oil can be synthetically prepared or purified from petroleum products.
  • Preferred non-metabolizable oils for use in the emulsions of the present invention include mineral oil, paraffin oil, and cycloparaffins, for example.
  • mineral oil refers to a mixture of liquid hydrocarbons obtained from petrolatum via a distillation technique.
  • the term is synonymous with “liquefied paraffin”, “liquid petrolatum” and “white mineral oil.”
  • the term is also intended to include “light mineral oil,” i.e., oil which is similarly obtained by distillation of petrolatum, but which has a slightly lower specific gravity than white mineral oil. See, e.g., Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pa.: Mack Publishing Company, 1990, at pages 788 and 1323).
  • Mineral oil can be obtained from various commercial sources, for example, J. T. Baker (Phillipsburg, Pa.), USB Corporation (Cleveland, Ohio).
  • Preferred mineral oil is light mineral oil commercially available under the name DRAKEOL®.
  • the oil component of the submicron emulsions of the present invention is present in an amount from 1% to 50% by volume; preferably, in an amount of 10% to 45; more preferably, in an amount from 20% to 40%.
  • the oil-in-water emulsions of the present invention typically include at least one (i.e., one or more) surfactant.
  • Surfactants and emulsifiers which terms are used interchangeably herein, are agents which stabilize the surface of the oil droplets and maintain the oil droplets within the desired size.
  • Surfactants suitable for use in the present emulsions include natural biologically compatible surfactants and non-natural synthetic surfactants.
  • Biologically compatible surfactants include phospholipid compounds or a mixture of phospholipids.
  • Preferred phospholipids are phosphatidylcholines (lecithin), such as soy or egg lecithin.
  • Lecithin can be obtained as a mixture of phosphatides and triglycerides by water-washing crude vegetable oils, and separating and drying the resulting hydrated gums.
  • a refined product can be obtained by fractionating the mixture for acetone insoluble phospholipids and glycolipids remaining after removal of the triglycerides and vegetable oil by acetone washing.
  • lecithin can be obtained from various commercial sources.
  • suitable phospholipids include phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphatidic acid, cardiolipin, and phosphatidylethanolamine.
  • the phospholipids may be isolated from natural sources or conventionally synthesized.
  • Non-natural, synthetic surfactants suitable for use in the submicron emulsions of the present invention include sorbitan-based non-ionic surfactants, e.g. fatty-acid-substituted sorbitan surfactants (commercially available under the name SPAN® or ARLACEL®), fatty acid esters of polyethoxylated sorbitol (TWEEN®), polyethylene glycol esters of fatty acids from sources such as castor oil (EMULFOR); polyethoxylated fatty acid (e.g., stearic acid available under the name SIMULSOL M-53), polyethoxylated isooctylphenol/formaldehyde polymer (TYLOXAPOL), polyoxyethylene fatty alcohol ethers (BRIJ®); polyoxyethylene nonphenyl ethers (TRITON® N), polyoxyethylene isooctylphenyl ethers (TRITON® X).
  • Preferred synthetic surfactants are the surfact
  • Preferred surfactants for use in the oil-in-water emulsions of the present invention include lecithin, Tween-80 and SPAN-80.
  • the surfactant or the combination of surfactants, if two or more surfactants are used, is present in the emulsion in an amount of 0.01% to 10% by volume, preferably, 0.1% to 6.0%, more preferably 0.2% to 5.0%.
  • the aqueous component constitutes the continuous phase of the emulsion and can be water, buffered-saline or any other suitable aqueous solution.
  • the oil-in-water emulsions of the present invention can include additional components that are appropriate and desirable, including preservatives, osmotic agents, bioadhesive molecules, and immunostimulatory molecules.
  • bioadhesive molecules can enhance the delivery and attachment of antigens on or through the target mucous surface conferring mucosal immunity.
  • suitable bioadhesive molecules include acidic non-naturally occurring polymers such as polyacrylic acid and polymethacrylic acid (e.g., CARBOPOL®), CARBOMER); acidic synthetically modified natural polymers such as carboxymethylcellulose; neutral synthetically modified natural polymers such as (hydroxypropyl) methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral non-naturally occurring polymers, such as polyvinylalcohol; or combinations thereof.
  • acidic non-naturally occurring polymers such as polyacrylic acid and polymethacrylic acid (e.g., CARBOPOL®), CARBOMER)
  • acidic synthetically modified natural polymers
  • immunostimulatory molecules refers to those molecules that enhance the protective immune response induced by an antigenic component in vaccine compositions.
  • Suitable immunostimulatory materials include bacterial cell wall components, e.g., derivatives of N-acetyl muramyl-L-alanyl-D-isoglutamine such as murabutide, threonyl-MDP and muramyl tripeptide; saponin glycosides and derivatives thereof, e.g., Quil A, QS 21 and GPI-0100; cholesterol; and quaternary ammonium compounds, e.g., dimethyldioctadecylammonium bromide (DDA) and N,N-dioctadecyl-N,N-bis(2-hydroxyethyl)propanediamine (“avridine”).
  • DDA dimethyldioctadecylammonium bromide
  • avridine N,N-dioctadecyl
  • Saponis are glycosidic compounds that are produced as secondary metabolites in a wide variety of plant species.
  • the chemical structure of saponins imparts a wide range of pharmacological and biological activities, including some potent and efficacious immunological activity.
  • saponins consist of any aglycone attached to one or more sugar chains. Saponins can be classified according to their aglycone composition: Triterpene glycosides, Steroid glycosides, and Steroid alkaloid glycosides.
  • Saponin can be isolated from the bark of Quillaja saponaria . Saponin has long been known as an immunostimulator. Dalsgaard, K., “Evaluation of its adjuvant activity with a special reference to the application in the vaccination of cattle against foot-and-mouth disease”, Acta. Vet. Scand. 69: 1-40 1978. Crude extracts of plants containing saponin enhanced potency of foot and mouth disease vaccines. However, the crude extracts were associated with adverse side effects when used in vaccines. Subsequently, Dalsgaard partially purified the adjuvant active component from saponin by dialysis, ion exchange and gel filtration chromatography. Dalsgaard, K.
  • QS21 has been shown to elicit a Th1 type response in mice stimulating the production of IgG2a and IgG2b antibodies and induced antigen-specific CD8+CTL (MHC class I) in response to subunit antigens.
  • Clinical studies in humans have proved its adjuvanticity with an acceptable toxicological profile.
  • Kensil, C. R. et al. “Structural and imunological charaterization of the vaccine adjuvant QS-21. In Vaccine Design: the subunit and Adjvuant Approach,” Eds. Powell, M. F. and Newman, M. J. Plenum Publishing Corporation, New York. 1995, pp. 525-541.
  • U.S. Pat. No. 6,080,725 teaches the methods of making and using saponin-lilpophile conjugate.
  • a lipophile moiety such as lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxy group present on the 3-O-glucuronic acid of the triterpene saponin.
  • a lipophilic moiety to the 3-O-glucuronic acid of a saponin such as Quillaja desacylsaponin , lucyoside P, or saponin from Gypsophila, saponaria and Acanthophyllum enhances their adjuvant effects on humoral and cell-mediated immunity. Additionally, the attachment of a lipophile moiety to the 3-O-glucuronic acid residue of non- or desacylsaponin yields a saponin analog that is easier to purify, less toxic, chemically more stable, and possesses equal or better adjuvant properties than the original saponin.
  • GPI-0100 is a saponin-lipophile conjugate described in the U.S. Pat. No. 6,080,725. GPI-0100 is produced by the addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid.
  • Quaternary ammonium compounds A number of aliphatic nitrogenous bases have been proposed for use as immunological adjuvants, including amines, quaternary ammonium compounds, guanidines, benzamidines and thiouroniums. Specific such compounds include dimethyldioctadecylammonium bromide (DDA) and N,N-dioctadecyl-N,N-bis(2-hydroxyethyl)propanediamine (“avridine”).
  • DDA dimethyldioctadecylammonium bromide
  • avridine N,N-dioctadecyl-N,N-bis(2-hydroxyethyl)propanediamine
  • U.S. Pat. No. 5,951,988 teaches adjuvant formulation containing quarternary ammonium salts such as DDA in conjunction with an oil component.
  • This formulation is useful in conjunction with known immunological substances, e.g., viral or bacterial antigens in a vaccine composition, in order to enhance the immunogenic response.
  • the composition is also useful without an incorporated antigen as nonspecific immunostimulatory formulation.
  • U.S. Pat. No. 4,310,550 describes the use of N,N-higher alkyl-N,N′-bis(2-hydroxyethyl)-propanediamine and N,N-higher alkyl-xylylenediamines formulated with fat or lipid emulsion as a vaccine adjuvant.
  • a method of inducing or enhancing the immunogenic response of an antigen in man or an animal through parenteral administration of the adjuvant formulation is described in the U.S. Pat. No. 4,310,550.
  • the present invention provides a submicron oil-in-water emulsion useful as vaccine adjuvant, which is composed of an AMPHIGEN® formulation, with droplets of a size less than 1 ⁇ m and a mean droplet size of about 0.25 ⁇ m.
  • AMPHIGEN® formulation refers to a solution formed by mixing a DRAKEOL® lecithin oil solution (Hydronics, Lincoln, NE) with saline solution in the presence of TWEEN® 80 and SPAN® 80.
  • a typical AMPHIGEN® formulation contains 40% light mineral oil by volume (v/v), about 25% w/v lecithin, about 0.18% TWEEN 80 by volume (v/v) and about 0.08% Span 80 by volume (v/v).
  • the present invention provides methods of preparing the submicron oil-in-water emulsions described hereinabove.
  • the various components of the emulsion including oil, one or more surfactants, an aqueous component and any other component appropriate for use in the emulsion, are combined and mixed together.
  • the mixture formed is subjected to an emulsification process, typically by passage one or more times through one or more homogenizers or emulsifiers to form an oil-in-water emulsion which has a uniform appearance and an average droplet size of about 0.5 ⁇ m.
  • Any commercially available homogenizer or emulsifier can be used for this purpose, e.g., Ross emulsifier (Hauppauge, N.Y.), Gaulin homogenizer (Everett, Mass.).
  • microfluidization can be achieved by use of a commercial mirofluidizer, such as model number 11 OY available from Microfluidics, Newton, Mass.; Gaulin Model 30CD (Gaulin, Inc., Everett, Mass.); and Rainnie Minilab Type 8.30H (Miro Atomizer Food and Dairy, Inc., Hudson, Wis.).
  • These microfluidizers operate by forcing fluids through small apertures under high pressure, such that two fluid streams interact at high velocities in an interaction chamber to form emulsions with droplets of a submicron size.
  • Droplet size can be determined by a variety of methods known in the art, e.g., laser diffraction, by use of commercially available sizing instruments. The size may vary depending on the type of surfactant used, the ratio of surfactant to oil, operating pressure, temperature, and the like. The skilled artisan can determine the desired combination of these parameters to obtain emulsions with desired droplet size without undue experimentation.
  • the droplets of the emulsions of the present invention are less than 1 ⁇ m in diameter, preferably with a mean droplet size of less than 0.8 ⁇ m, and more preferably with a mean droplet size less than 0.5 ⁇ m, and even more preferably with a mean droplet size of less than 0.3 ⁇ m.
  • the DRAKEOL lecithin oil solution which is commercially available from Hydronics (Lincoln, Nebr.) and contains 25% lecithin in light mineral oil, is combined and mixed with saline as well as surfactants TWEEN® 80 and SPAN® 80 to form an “AMPHGEN® solution” or “AMPHIGEN® formulation”.
  • the AMPHGEN® solution is then emulsified with a Ross® (Hauppauge, N.Y. 11788) emulsifier at approximately 3400 rpm to form an oil-in-water emulsion.
  • the emulsion is passed once through a Microfluidizer operating at about 4500 ⁇ 500 psi.
  • the microfluidized oil-in-water emulsion has droplets of a size less than 1 ⁇ m, with a mean droplet size of about 0.25 ⁇ m.
  • the present invention provides vaccine compositions which contain an antigen(s) and a submicron oil-in-water emulsion described hereinabove. These vaccine compositions are characterized by having an enhanced immunogenic effect and an improved physical appearance (e.g., no phase separation is observed after an extended period of storage). In addition, the vaccine compositions of the present invention are safe for administration to animals.
  • the antigen can be combined with the emulsion extrinsically, or preferably, intrinsically.
  • the term “intrinsically” refers to the process wherein the antigen is combined with the emulsion components prior to the microfluidization step.
  • the term “extrinsically” refers to the process where the antigen is added to the emulsion after the emulsion has been microfluidized.
  • the extrinsically added antigen can be free antigen or it can be encapsulated in microparticles as further described herein below.
  • antigen refers to any molecule, compound or composition that is immunogenic in an animal and is included in the vaccine composition to elicit a protective immune response in the animal to which the vaccine composition is administered.
  • the term “immunogenic” as used in connection with an antigen refers to the capacity of the antigen to provoke an immune response in an animal against the antigen.
  • the immune response can be a cellular immune response mediated primarily by cytotoxic T-cells, or a humoral immune response mediated primarily by helper T-cells, which in turn activates B-cells leading to antibody production.
  • a “protective immune response” is defined as any immune response, either antibody or cell mediated immune response, or both, occurring in the animal that either prevents or detectably reduces the occurrence, or eliminates or detectably reduces the severity, or detectably slows the rate of progression, of the disorder or disease caused by the antigen or a pathogen containing the antigen.
  • Antigens which can be included in the vaccine composition of the present invention include antigens prepared from pathogenic bacteria such as Mycoplasma hyopneumoniae, Haemophilus somnus, Haemophilus parasuis, Bordetella bronchiseptica, Actinobacillus pleuropneumonie, Pasteurella multocida, Manheimia hemolytica, Mycoplasma bovis, Mycoplasma galanacieum, Mycobacterium bovis, Mycobacterium paratuberculosis, Clostridial spp., Streptococcus uberis, Streptococcus suis, Staphylococcus aureus, Erysipelothrix rhusopathiae, Campylobacter spp., Fusobacterium necrophorum, Escherichia coli, Salmonella enterica serovars, Leptospira spp.; pathogenic fungi such as Candida ; proto
  • Additional antigens include pathogenic viruses such as Bovine herpesviruses-1,3,6, Bovine viral diarrhea virus (BVDV) types 1 and 2, Bovine parainfluenza virus, Bovine respiratory syncytial virus, bovine leukosis virus, rinderpest virus, foot and mouth disease virus, rabies, swine fever virus, African swine fever virus, Porcine parvovirus, PRRS virus, Porcine circovirus, influenza virus, swine vesicular disease virus, Techen fever virus, Pseudorabies virus, either in the form of an inactivated whole or partial virus preparation, or in the form of antigenic molecules obtained by conventional protein purification, genetic engineering techniques or chemical synthesis.
  • BVDV Bovine herpesviruses-1,3,6, Bovine viral diarrhea virus (BVDV) types 1 and 2
  • Bovine parainfluenza virus Bovine respiratory syncytial virus
  • bovine leukosis virus bovine leukosis virus
  • rinderpest virus bo
  • the amount of the antigen should be such that the antigen which, in combination with the oil-in-water emulsion, is effective to induce a protective immune response in an animal.
  • the precise amount of an antigen to be effective depends on the nature, activity and purity of the antigen, and can be determined by one skilled in the art.
  • the amount of the oil-in-water emulsion present in the vaccine compositions should be sufficient for potentiating the immunogenicity of the antigen(s) in the vaccine compositions.
  • additional amounts of surfactant(s) or additional surfactant(s) can be added in the vaccine composition in addition to the surfactant(s) provided by the oil-in-water emulsion.
  • the oil component is present in the final volume of a vaccine composition in an amount from 1.0% to 20% by volume; preferably, in an amount of 1.0% to 10%; more preferably, in an amount from 2.0% to 5.0%.
  • the surfactant, or the combination of surfactants if two or more surfactants are used, is present in the final volume of a vaccine composition in an amount of 0.1% to 20% by volume, preferably, 0.15% to 10%, more preferably 0.2% to 6.0%.
  • the vaccine composition can include other components which are appropriate and desirable, such as preservatives, osmotic agents, bioadhesive molecules, and immunostimulatory molecules (e.g., Quil A, cholesterol, GPI-0100, dimethyldioctadecylammonium bromide (DDA)), as described hereinabove in connection with the oil-in-water emulsion.
  • preservatives e.g., osmotic agents, bioadhesive molecules, and immunostimulatory molecules (e.g., Quil A, cholesterol, GPI-0100, dimethyldioctadecylammonium bromide (DDA)
  • DDA dimethyldioctadecylammonium bromide
  • the vaccine compositions of the present invention can also include a veterinarily-acceptable carrier.
  • a veterinarily-acceptable carrier includes any and all solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like.
  • Diluents can include water, saline, dextrose, ethanol, glycerol, and the like.
  • Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others.
  • Stabilizers include albumin, among others.
  • the present invention provides a vaccine composition which includes at least one of a BVDV type I or BVDV type II antigen, incorporated intrinsically in an oil-in-water emulsion which has droplets of a size of less than 1 ⁇ m, preferably with a mean droplet size of less than 0.8 ⁇ m, more preferably less than 0.5 ⁇ m, and even more preferably with a mean droplet size of about 0.5 ⁇ m.
  • the BVDV type I and/or II antigen is preferably in the form of an inactivated viral preparation.
  • the submicron oil-in-water emulsion preferably is composed of an AMPHIGEN® formulation (i.e., a formulation which contains light mineral oil, lecithin, TWEEN® 80, and SPAN® 80).
  • the vaccine composition preferably also includes Quil-A, cholesterol, and thimerosol.
  • the present invention provides a vaccine composition which includes a Leptospira antigen and at least one of a BVDV type I or BVDV type II antigen in an oil-in-water emulsion.
  • the antigens preferably in the form of inactivated cell or viral preparation, are incorporated intrinsically in the oil-in-water emulsion having droplets of a size of less than 1 ⁇ m, preferably with a mean droplet size of less than 0.8 ⁇ m, more preferably less than 0.5 ⁇ m, and even more preferably with a mean droplet size of about 0.5 ⁇ m.
  • the submicron oil-in-water emulsion preferably is composed of an AMPHIGEN formulation (i.e., a formulation which contains light mineral oil, lecithin, TWEEN® 80, and SPAN® 80).
  • the vaccine composition preferably also includes one or more immunostimulatory molecules selected from Quil-A, cholesterol, DDA, GPI-100 and aluminum hydroxide (AIOH).
  • the present invention provides a vaccine composition which includes at least one bacterial antigen, e.g., the recombinant Streptococcus uberis PauA protein or a cell preparation of E. coli or a combination of both, in an oil-in-water emulsion.
  • the antigen(s) is combined intrinsically with the oil-in-water emulsion which has droplets of a size of less than 1 ⁇ m, preferably with a mean droplet size of less than 0.8 ⁇ m, more preferably less than 0.5 ⁇ m, and even more preferably with a mean droplet size of about 0.25 ⁇ m.
  • the submicron oil-in-water emulsion preferably is composed of an AMPHIGEN® formulation (i.e., a formulation which contains light mineral oil, lecithin, TWEEN® 80, and SPAN® 80).
  • the vaccine composition preferably also includes one or more immunostimulatory molecules selected from Quil A, DDA and GPI-100.
  • the vaccine compositions of the present invention can be administered to an animal by known routes, including the oral, intranasal, mucosal, topical, transdermal, and parenteral (e.g., intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular) route. Administration can be achieved using a combination of routes, e.g., first administration using a parental route and subsequent administration using a mucosal route.
  • routes including the oral, intranasal, mucosal, topical, transdermal, and parenteral (e.g., intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular) route.
  • Administration can be achieved using a combination of routes, e.g., first administration using a parental route and subsequent administration using a mucosal route.
  • the present invention provides methods of preparing vaccine compositions containing an antigen or antigens and a submicron oil-in-water emulsion.
  • the antigen(s) can be combined either intrinsically or extrinsically with the components of the oil-in-water emulsion.
  • the antigen is combined with the components of the oil-in-water emulsion intrinsically.
  • the antigen can be combined with the various components of the emulsion, including oil, one or more surfactants, an aqueous component and any other appropriate component, to form a mixture.
  • the mixture is subjected to a primary blending process, typically by passage one or more times through one or more homogenizers or emulsifiers, to form an oil-in-water emulsion containing the antigen.
  • Any commercially available homogenizer or emulsifier can be used for this purpose, e.g., Ross emulsifier (Hauppauge, N.Y.), Gaulin homogenizer (Everett, Mass.), or Microfluidics (Newton, Mass.).
  • the various components of the emulsion adjuvant including oil, one or more surfactants, and an aqueous component can be combined first to form an oil-in-water emulsion by using a homogenizer or emulsifier; and the antigen is then added to this emulsion.
  • the mean droplet size of the oil-in-water emulsion after the primary blending is approximately 1.0-1.2 micron.
  • microfluidization can be achieved by use of a commercial mirofluidizer, such as model number 11OY available from Microfluidics, Newton, Mass.; Gaulin Model 30CD (Gaulin, Inc., Everett, Mass.); and Rainnie Minilab Type 8.30H (Miro Atomizer Food and Dairy, Inc., Hudson, Wis.).
  • model number 11OY available from Microfluidics, Newton, Mass.
  • Gaulin Model 30CD Gaulin, Inc., Everett, Mass.
  • Rainnie Minilab Type 8.30H Miro Atomizer Food and Dairy, Inc., Hudson, Wis.
  • Droplet size can be determined by a variety of methods known in the art, e.g., laser diffraction, by use of commercially available sizing instruments.
  • the size may vary depending on the type of surfactant used, the ratio of surfactant to oil, operating pressure, temperature, and the like. One can determine a desired combination of these parameters to obtain emulsions with a desired droplet size.
  • the oil droplets of the emulsions of the present invention are less than 1 ⁇ m in diameter.
  • the mean droplet size is less than 0.8 ⁇ m. More preferably, the mean droplet size is less than 0.5 ⁇ m. Even more preferably, the mean droplet size is about 0.1 to 0.3 ⁇ m.
  • the DRAKEOL® lecithin oil solution which contains 25% lecithin in light mineral oil, is combined and mixed with surfactants TWEEN® 80 and SPAN® 80 and saline solution to form a mixture that contains 40% light mineral oil, lecithin, 0.18% TWEEN® 80, and 0.08% SPAN® 80.
  • the mixture is then emulsified with a Ross® (Hauppauge, N.Y. 11788) emulsifier at approximately 3400 rpm to form an emulsion product, which is also referred to as an “AMPHIGEN® formulation” or “AMPHIGEN® solution”.
  • the desired antigen(s) are combined with the AMPHIGEN® solution and any other appropriate components (e.g., immunostimulatory molecules) with the aid of an emulsifier, e.g., a Ross homogenizer, to form an oil-in-water emulsion containing the antigen(s).
  • an emulsifier e.g., a Ross homogenizer
  • Such emulsion is passed once through a Microfluidizer operating at about 10000 ⁇ 500 psi.
  • the microfluidized oil-in-water emulsion has droplets of a size of less than 1 ⁇ m, with the mean droplet size of about 0.25 ⁇ m.
  • an oil-in-water emulsion e.g., an AMPHIGEN® formulation
  • the antigen(s) is combined with a saponin glycoside, e.g., Quil A, to form a mixture.
  • This antigen(s)-saponin mixture is subjected to homogenization, e.g., in a homogenization vessel.
  • a sterol e.g., cholesterol, is then added to the homogenized antigen(s)-saponin mixture.
  • the mixture containing the antigen(s), saponin and sterol is then subjected to further homogenization.
  • the homogenized antigen(s)-saponin-sterol mixture is then combined with an oil-in-water emulsion (e.g., an AMPHIGEN) formulation) with the aid of a homogenizer, for example.
  • an oil-in-water emulsion e.g., an AMPHIGEN
  • the homogenized oil-in-water emulsion containing the antigen(s), saponin and sterol is then subjected to high pressure homogenization, such as microfluidization.
  • the present invention provides vaccine compositions which contain an antigen encapsulated in microparticles (or “microencapsulated antigen”), where the microencapsulated antigen is extrinsically incorporated into a submicron oil-in-water emulsion described hereinabove.
  • Particulate Carriers Therapeutic Applications (Justin Hanes, Masatoshi Chiba and Robert Langer. Polymer microspheres for vaccine delivery. In: Vaccine design. The subunit and adjuvant approach. Eds. Michael F. Powell and Mark J. Newman, 1995 Plenum Press, New York and London ).
  • Particulate carriers can present multiple copies of a selected antigen to the immune system in an animal subject and promote trapping and retention of antigens in local lymph nodes.
  • the particles can be phagocytosed by macrophages and can enhance antigen presentation through cytokine release.
  • Particulate carriers have also been described in the art and include, e.g., those derived from polymethyl methacrylate polymers, as well as those derived from poly(lactides) and poly(lactide-co-glycolides), known as PLG.
  • Polymethyl methacrylate polymers are non-biodegradable while PLG particles can be biodegrade by random non-enzymatic hydrolysis of ester bonds to lactic and glycolic acids which are excreted along normal metabolic pathways.
  • Biodegradable microspheres have also used to achieve controlled release of vaccines. For example, a continuous release of antigen over a prolonged period can be achieved. Depending upon the molecular weight of the polymer and the ratio of lactic to glycolic acid in the polymer, a PLGA polymer can have a hydrolysis rate from a few days or weeks to several months or a year. A slow, controlled release may result in the formation of high levels of antibodies similar to those observed after multiple injections. Alternatively, a pulsatile release of vaccine antigens an be achieved by selecting polymers with different rates of hydrolysis. The rate of hydrolysis of a polymer typically depends upon the molecular weight of the polymer and the ratio of lactic to glycolic acid in the polymer. Microparticles made from two or more different polymers with varying rates of antigen release provide pulsatile releases of antigens and mimics multiple-dose regimes of vaccination.
  • an antigen including any of those described hereinabove, can be absorbed to a particulate polymer carrier, preferably a PLG polymer, by using any procedure known in the art (such as one exemplified in Example 17), to form a microencapsulated antigen preparation.
  • the microencapsulated antigen preparation is then mixed with and dispersed in a submicron oil-in-water emulsion, which emulsion has been described hereinabove, to form the vaccine composition.
  • the present invention provides a vaccine composition which contains an antigen encapsulated in a PLG polymer, wherein the microencapsulated antigen is dispersed extrinsically in a microfluidized oil-in-water emulsion which is composed of light mineral oil, lecithin, TWEEN80, SPAN80 and saline, and has a mean droplet size of less than 1.0 ⁇ m.
  • An AMPHIGEN® formulation was prepared in a two-step process.
  • 80 liters of Drakeol Lecithin oil solution, 116 liters of Tetanus Toxoid saline, 1.2 liters of SPAN 80, and 2.8 liters of Tween 80 were mixed together and emulsified using a Ross emulsifier.
  • the Drakeol Lecithin oil solution contained 25% soya lecithin and 75% mineral oil.
  • Emulsified product was recirculated through Ross emulsifier for a minimum of 5 volumes or a minimum of 10 minutes.
  • the emulsified product was stored at 2-7° C. for a maximum of 24 hours for further processing.
  • AMPHIGEN® Drakeol Lecithin oil solution
  • FIG. 1 The apparatus used for this homogenization process is shown in FIG. 1.
  • a bottle containing an BVD Type I antigen (an inactivated BVD Type I viral preparation) was attached to the bottom side port on the blend vessel.
  • the BVD Type I bottle was replaced with the bottle containing an inactivated BVD Type II viral preparation (an inactivated BVD type II viral preparation).
  • the Ross homogenizer was attached to the portable vessel and the recirculation was initiated at maximum RPM (3300 rpm). Vessel agitation was maintained at medium speed.
  • a bottle containing Quil-A at 50 mg/ml concentration was attached to the homogenizer in-line port on the blend vessel.
  • a required amount of the Quil-A solution was passed into the vessel through line suction. After the transfer of the Quil-A solution was completed, the bottle was removed.
  • a required amount of cholesterol in ethanol solution (18 mg/ml) was transferred to the blend vessel.
  • a required amount of the AMPHIGEN® formulation, 10% thimerosol solution, and Basic Modified Eagles media (“BME”) extender solutions were added to the blend vessel.
  • the resulting formulation was aliquoted into 2 ml doses and represented a non-microfluidized AMPHIGEN® formulation-based BVD vaccine.
  • Each dose of the vaccine contained 500 ⁇ g Quil-A, 500 ⁇ g Cholesterol, 2.5% AMPHIGEN® formulation and 0.009% thimerosol.
  • the antigen concentration for the two different BVD strains was determined in terms of the ELISA titer for gp53.
  • FIG. 2 illustrates the process used for the secondary blending through microfluidization.
  • the microfluidizer was steam sterilized.
  • First the auxiliary processing module chamber was installed in the unit and the blank chamber was installed on the second chamber position.
  • the vessel containing the fully adjuvanted BVD vaccine prepared as described in the Example 2 was connected to the microfluidizer by attaching a transfer line from the supply vessel drain valve to the microfluidizer inlet. Nitrogen gas was connected to the supply vessel air filter inlet and the vessel pressure setting was adjusted to 20+/ ⁇ 5 PSI. Collection vessel drain valve was connected to the transfer line from the microfluidizer outlet.
  • microfluidization was initiated at an operating pressure of 10,000+/ ⁇ 500 PSI.
  • the entire content of the vaccine was passed through the microfluidizer one time and was collected in the post-microfluidization chamber. This preparation was aliquoted into 2 mL doses and represents the microfluidized AMPHIGEN® formulation-based BVD vaccine.
  • the AMPHIGEN® formulation prepared as described in Example 1 was diluted to the 2.5% with the addition of BVD antigens and the extender. The resulting solution was blended at the bench using a stir bar instead of using a homogenizer. The final preparation contained the following composition: BVD Type 1 and Type 2 antigens, 2.5% AMPHIGEN® formulation (which contains oil, lecithin, SPAN® and TWEEN®, as described in Example 1), and saline. TWEEN 80 and SPAN 80 are present in the final vaccine preparation at 0.18% and 0.08% by volume, respectively.
  • the non-microfluidized AMPHIGEN® formulation-based vaccine prepared as described in the Example 2 was used to compare the droplet size of the vaccine preparations. Two mililiters of the sample from each of the preparations were added to a Malvern 2000 Laser Diffraction meter and the droplet size distribution was determined. As shown in FIG. 3, the results indicate that the microfluidized AMPHIGEN® formulation-based vaccine preparation had the maximum particle volume around 0.1 micron while the non-microfluidized AMPHIGEN® formulation-based vaccine preparation had the maximum particle distribution volume around 1 micron.
  • Bovine Virus Diarrhea viral antigen was intrinsically incorporated into the AMPHIGEN® formulation through microfluidization.
  • the term “intrinsically incorporated” refers to the process whereby the antigen was added to the AMPHIGEN® formulation prior to the microfluidization. The antigen was subjected to the physical forces of the microfluidization process along with the components of the adjuvant formulation. In the control non-microfluidized group, the antigen preparation was dispersed in the AMPHIGEN® formulation through blending.
  • BVD type I with a post-inactivation ELISA titer of 2535 RU/ dose for gp53
  • BVD Type II with a post-inactivation ELISA titer of 3290 RU/dose for gp53
  • Quil-A at the concentration of 1.25 mg/dose
  • cholesterol at the concentration of 1.25 mg/dose
  • the AMPHIGEN® formulation at the final concentration of 2.5%
  • thimerosol at the final concentration of 0.009%.
  • the vaccine dose was 5 ml.
  • microfluidized and non-microfluidized vaccine preparations made as described in Example 7 were used to vaccinate the cattle on day zero and the rectal temperature was monitored during the period from one day prior to vaccination till four days post vaccination.
  • the vaccine dose was 2 ml.
  • the groups were vaccinated either with a single or double dose of the vaccine. Rectal temperatures were measured and recorded daily on Day -1 through Day 4, inclusive. Rectal temperatures on day 0 were measured prior to administration of test article.
  • the microfluidized and non-microfluidized vaccine preparations made as described in the Example 7 were used to vaccinate the cattle on day zero.
  • the animals included in this study were cross-bred beef cattle.
  • the vaccine dose was 2 ml and the groups were vaccinated either with one or two doses of the vaccine on day zero.
  • test article was administered in the right neck. Animals receiving the double dose (4 ml) of the test article (T02, T04, and T06) received the entire double dose as a single injection at one side.
  • injection sites including estimation of reaction size at the injection site were made on the right side of the neck on Day 0 through Day 4, inclusive, and Days 6, 9, and 14. On Day 0 injection sites were observed prior to administration of test articles.
  • the groups vaccinated with one or two doses of the placebo did not show any significant increase in the injection site reaction volume and therefore those data are not shown in the FIG. 7.
  • the non-microfluidized vaccine formulation there was a proportional increase in the injection site reaction volume between the one dose and two dose vaccination.
  • the microfluidized vaccine formulation although the single dose induced a larger injection site reaction volume, the injection with second dose did not cause any further increase.
  • Formalin-inactivated Leptospira hardjo - bovis strain CSL was formulated in the appropriate adjuvant at direct counts of about 1.4 ⁇ 10 9 organisms/5 ml dose.
  • Formalin-inactivated Leptospira Pomona strain T262 was formulated at about 2400 Nephalomeric Units/5 ml dose. Nephalomeric units were calculated based on nephalometric measurement of preprocessed fermentation fluid.
  • BVD virus Type 1 was formulated at E2 Elisa titer of about 3000 Relative Units/5 ml dose.
  • BVD virus Type 2 was formulated at E2 Elisa titer of about 3500 Relative Units/5 ml dose.
  • the Relative Unit was calculated based on the E2 ELISA titer of pre-assembly post-inactivation bulk fluid. Both Quil-A and cholesterol were used at the concentration of 0.5 mg per dose. Thimerosol and the AMPHIGEN® formulation were used at the final concentration of 0.009% and 2.5%, respectively. Aluminum hydroxide (Rehydragel LV) was used at the final concentration of 2.0%. When DDA was used as an immunomodulator, DDA was included within the AMPHIGEN® formulation.
  • the AMPHIGEN® formulation (i.e., the 40% Drakeol-lecithin stock solution) contained 1.6 mg/ml of DDA and, when appropriately diluted, the final vaccine preparation contained 2.5% AMPHIGEN® formulation and 0.1 mg/ml of DDA.
  • BVD fractions In the preparation of different vaccine formulations, BVD fractions, Leptos, Quil-A, chloestrol, thimerosol, the AMPHIGEN® formulation, and saline as an extender were added to a Silverson homogenizer and mixed for 15 minutes at 10,000 ⁇ 500 RPM. Components were then microfluidized through a 200 micron screen at 10,000 psi.
  • the microfluidization was carried out without aluminum hydroxide. After the microfluidization was completed, aluminum hydroxide was added and mixed with a stir bar overnight at 4° C.
  • the vaccine preparation used in this experiment contained antigens from both BVD virus Type 1 and BVD Virus Type 2.
  • BVD1 -5960 antigen was used at the post-inactivation ELISA titer of 2535 RU/dose for gp53.
  • BVD2-890 antigen was used at the post-inactivation ELISA titer of 3290 RU/dose for gp53.
  • Quil A and cholesterol were used at the concentration of 0.5 mg/ml.
  • Thimersol and the AMPHIGEN® formulation were used at the final concentration of 0.009% and 2.5%, respectively.
  • DDA was included within the the AMPHIGEN® formulation.
  • the AMPHIGEN® stock solution (40% Drakeol-lecithin solution) contained varying amounts of DDA and when appropriately diluted, the final vaccine preparation contained 2.5% AMPHIGEN®) formulation and DDA concentration ranging from 0.5 mg/dose to 2.0 mg/dose.
  • Aluminum gel (Rehydragel-LV) was used at the final concentration of 2%.
  • GPI-0100 was used in the range of 2, 3, and 5 mg/dose.
  • Treatment group Composition of adjuvant T01 Salilne T02 Quil-A, Cholesterol, and the AMPHIGEN ® formulation (QAC) T03 Quil-A, Cholesterol, the AMPHIGEN ® formulation and AIOH (QAC-AIOH) T04 DDA, Cholesterol, and the AMPHIGEN ® formulation (DDA) T05 DDA, Cholesterol, the AMPHIGEN ® formulation, and AIOH (DDA-AIOH)
  • Table 1 shows the composition of the adjuvant formulations in the vaccine preparations tested in this study.
  • the vaccine preparations were prepared as described in the Example 11. There were six animals in each group. About seven-month old beef cross-bred heifers were used in this study. Vaccination was done on Day 0 and Day 21 through subcutaneous route with 5 ml vaccine volume. Challenge was done with L. hardjo - bovis strain 203 from NADC (National agricultural Disease Center). Challenge was done during Days 57-59 with a 1-ml innoculum. Challenge was administered conjunctively in the eye and vaginally. The challenge material contained 5.0 ⁇ 10 6 leptospires/ml. Urine was collected weekly for lepto culture, FA and PCR.
  • Table 2 shows the data from the Leptospira challenge study. In determining the percentage of Leptospira infection in the challenged animal, the following criteria were used. If the kidney culture was positive for only one sample, the animal is considered to be positive for Leptospira . If an animal is positive in only one sample for either FA or PCR, the animal is considered to be negative. If the sample is positive for both FA and PCR in only one sample, it was considered positive for Leptospira.
  • Treatment Adjuvant composition T01 Saline T02 Quil-A, AMPHIGEN ® formulation, and Chloesterol T03 AMPHIGEN ® formulation, Choloesterol, DDA (0.5 mg/dose) and AIOH T04 AMPHIGEN ® formulation, Cholesterol, and DDA (0.5 mg/dose) T05 AMPHIGEN ® formulation, Cholesterol, and DDA (1.0 mg/dose) T06 AMPHIGEN ® formulation, Cholesterol, and DDA (2.0 mg/dose)
  • a 5 ml dose of the challenge virus preparation (approximately 2.5 ml per nostril) was administered intranasally on Day 44 of the study.
  • Retained samples of challenge material were tittered (two replicates per titration) at the time challenge was initiated and immediately upon its completion.
  • the mean live virus titer per 5 ml dose was 5.3 log 10 FAID 50 /5 ml prior to challenge and 5.4 log 50 FAID 50 /5 ml post challenge (FAID is equivalent to TCID 50 ).
  • Leukopenia was defined as a 40% or greater decrease in the WBC count from baseline (average of pre-challenge WBC counts from two days prior to, and the day of challenge).
  • Geometric mean SVN titer Treatment 0 21 35 43 57 T01 Saline ⁇ 2 ⁇ 2 ⁇ 2 ⁇ 2 35.5 T02 Amphigen, Quil A ⁇ 2 98.7 20171.0 12203.4 44762.4 T03 Amphigen, 2 mg ⁇ 2 84.6 10998.5 7383.2 25709.2 GPI-0100, AlOH T04 Amphigen, 2 mg ⁇ 2 106.0 18179.2 8933.2 28526.2 GPI-0100 T05 Amphigen, 3 mg ⁇ 2 62.9 15024.3 8780.1 19824.4 GPI-0100 T06 Am,phigen, 5 mg ⁇ 2 71.1 12203.3 7512.0 16670.2 GPI-0100
  • Trehalose Three grams was added to water to get a stock of 333mg/ml of Trehalose solution. Recombinant PauA antigen solubililzed in 0.8% SDS solution (SDS/rPauA) was added to Trehalose solution to get a final concentration of 494 ⁇ g rPauA/ml.
  • SDS/rPauA Recombinant PauA antigen solubililzed in 0.8% SDS solution
  • PLG- Resomer RE 503H polylactide glycolic acid
  • MeCl2 Methylene Chloride
  • the combined solution was subjected to microfluidization using (Microfluidizer from Microfluidics Model M110EH) and the microfluidized preparation was spray dried using (Temco Spray Dryer Model SD-05). The spray dried material was collected using a 500 micron screen.
  • the concentration of rPauA in this spray dried material was quantified using a Western blot analysis. 1.04 mg of spray-dried material was dissolved in 50 ⁇ l of acetone and centrifuged at 13,200 rpm at room temperature for 10 minutes. The supernatant was removed. The supernatantand the pellet fractions were dried in a biological safety hood for 2.5 hours. The pellet was resuspended in 47.43 ⁇ L of sample solution (25 ⁇ l of sample buffer +10 ⁇ l of reducing agent+65 ⁇ l of water). The dried supernatant fraction was resuspended with 20 ⁇ l of sample solution. In the western analysis purified PauA was used as a standard to quantify the rPauA content of the spray dried material.
  • a 20% Manitol stock solution was prepared by dissolving 100 grams of mannitol (Sigma) in 500 ml of Water for Injection (WFI). Solution was heated to 40° C. with hot plate/stirrer and cooled to 30° C. Solution was sterile filtered through a 0.22 micron sterile filter (Millipore). 2.5% Carboxymethylcellulose solution was prepared by dissolving 12.5 grams of carboxymethyulcellulose (Sigma) in 500 ml of WFI and mixed overnight at 4° C. Solution was autoclaved at 121° C.
  • the powder resulting from spray drying was reconstituted in a solution containing 5% mannitol, 0.3% carboxymethyl cellulose, and 1:5000 of thimerosol.
  • the final solution was aliquoted in to 3 ml vials and lyophilized using a Lyophilizer (USIFROID).
  • USIFROID Lyophilizer
  • the lyophilized powder represents the microencapsulated rPauA.
  • the microencapsulated subunit protein antigen is resuspended in 2 ml of microfluidized oil-in-water emulsion containing an AMPHIGEN® formulation (such as the microfluidized emulsion described in Example 20) and used as a vaccine.
  • Two vaccine preparations were made which contained both recombinant Streptococcus uberis PauA protein and Escherichia coli bacterial cells, added intrinsically to oil-in-water emulsions as described in Examples 2 and 3.
  • the recombinant PauA antigen was at the concentration of 100 ⁇ g per dose and the E. coli cells were at the final count of 4 ⁇ 10 per dose.
  • the emulsion adjuvant compositions of the two vaccine formulations are shown in the Table 16. TABLE 16 Vaccine formulations containing both the recombinant protein and whole E. coli cells.
  • Treatment Antigen Adjuvant T01 Placebo Saline T02 Pau A/ E. coli SEAM-14 T03 Pau A/ E.
  • the antibody titer for E. coli antigen is shown in FIG. 9.
  • the antibody titer for E. coli antigen was comparable in both vaccine formulations, although the presence of GPI-0100 as an immunostimulant induced a relatively higher antibody titer when compared to the formulation with DDA as an immunostimulant.
  • microfluidization inactivates the virus, the viricidal activity of three microfluidized AMPHIGEN® formulation based vaccine preparations were determined.
  • the three preparations contained three different bovine infectious viruses, namely bovine herpes virus (BHV), parainfluenza virus 3 (PI3), and bovine respiratory synctial virus (BRSV).
  • BHV bovine herpes virus
  • PI3 parainfluenza virus 3
  • BRSV bovine respiratory synctial virus
  • a value above 0.7 is an indication of viricidal effect.
  • An AMPHIGEN® formulation was prepared by combining the DRAKEOL lecithin oil solution (light mineral oil with 25% lecithin) and TWEEN 80 (with the final concentration of 0.18%) and Span 80 (with the final concentration of 0.08%) with mixing for 8-22 hours at 36 ⁇ 1° C. The oil mixture was then added to saline with the aide of a Ross® (Hauppauge, N.Y. 11788) emulsifier at approximately 3400 rpm. Subsequently the mixture was passed once through a microfluidizer with a 200 ⁇ m interaction chamber at 4500 ⁇ 500 psi.
  • FIGS. 10A and 10B show the stability of the microfluidized AMPHIGEN® formulation. Particle size distribution, as measured by laser diffraction, at the starting, initial time point (FIG. 10A) was nearly identical to the particle size distribution after 22 months of 4° C. storage (FIG. 10B).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
US10/818,433 2003-04-04 2004-04-05 Microfluidized oil-in-water emulsions and vaccine compositions Abandoned US20040258701A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/818,433 US20040258701A1 (en) 2003-04-04 2004-04-05 Microfluidized oil-in-water emulsions and vaccine compositions
US12/650,715 US8771727B2 (en) 2003-04-04 2009-12-31 Microfluidized oil-in-water emulsions and vaccine compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46030103P 2003-04-04 2003-04-04
US10/818,433 US20040258701A1 (en) 2003-04-04 2004-04-05 Microfluidized oil-in-water emulsions and vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/650,715 Division US8771727B2 (en) 2003-04-04 2009-12-31 Microfluidized oil-in-water emulsions and vaccine compositions

Publications (1)

Publication Number Publication Date
US20040258701A1 true US20040258701A1 (en) 2004-12-23

Family

ID=33131921

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/818,433 Abandoned US20040258701A1 (en) 2003-04-04 2004-04-05 Microfluidized oil-in-water emulsions and vaccine compositions
US12/650,715 Expired - Lifetime US8771727B2 (en) 2003-04-04 2009-12-31 Microfluidized oil-in-water emulsions and vaccine compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/650,715 Expired - Lifetime US8771727B2 (en) 2003-04-04 2009-12-31 Microfluidized oil-in-water emulsions and vaccine compositions

Country Status (25)

Country Link
US (2) US20040258701A1 (pl)
EP (1) EP1613346B8 (pl)
JP (1) JP2006522090A (pl)
KR (1) KR100720213B1 (pl)
CN (1) CN1767854B (pl)
AR (1) AR043803A1 (pl)
AU (1) AU2004226591B2 (pl)
BR (1) BRPI0408635B1 (pl)
CA (1) CA2521051C (pl)
CL (1) CL2004000691A1 (pl)
CY (1) CY1113546T1 (pl)
DK (1) DK1613346T3 (pl)
ES (1) ES2398235T3 (pl)
HK (1) HK1086484A1 (pl)
MX (1) MXPA05010697A (pl)
NO (1) NO20054376L (pl)
NZ (1) NZ542576A (pl)
PL (1) PL1613346T3 (pl)
PT (1) PT1613346E (pl)
RU (2) RU2541809C2 (pl)
SI (1) SI1613346T1 (pl)
TW (1) TWI353850B (pl)
UY (1) UY28256A1 (pl)
WO (1) WO2004087204A2 (pl)
ZA (1) ZA200507994B (pl)

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043041A1 (en) * 1999-04-28 2004-03-04 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US20050019339A1 (en) * 2000-11-07 2005-01-27 Brown Robert George Vaccines with enhanced immune response and methods for their preparation
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US20070054834A1 (en) * 2005-04-11 2007-03-08 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
US20080020018A1 (en) * 2004-09-27 2008-01-24 Joey Moodley Combination Products
US20080112970A1 (en) * 2006-09-11 2008-05-15 Pfizer Inc. Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US20100203120A1 (en) * 2007-04-04 2010-08-12 Ivan Coulter Pharmaceutical cyclosporin compositions
DE102009056883A1 (de) * 2009-12-03 2011-06-09 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
WO2011018504A3 (en) * 2009-08-12 2011-06-23 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US20110162982A1 (en) * 2009-12-03 2011-07-07 Novartis Vaccines and Diagnostic, GmbH & Co. KG Methods for producing vaccine adjuvants
US20110165193A1 (en) * 2009-12-03 2011-07-07 Novartis Vaccines and Diagnostics, GmbH & Co. KG Methods for producing vaccine adjuvants
EP2380558A1 (en) * 2009-12-03 2011-10-26 Novartis AG Arranging interaction and back pressure chambers for microfluidization
US20140227684A1 (en) * 2013-02-08 2014-08-14 10X Technologies, Inc. Partitioning and processing of analytes and other species
US8895629B2 (en) 2009-12-03 2014-11-25 Novartis Ag Circulation of components during homogenization of emulsions
US20150335574A1 (en) * 2005-07-18 2015-11-26 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US9220681B2 (en) 2012-07-05 2015-12-29 Sigmoid Pharma Limited Formulations
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
US9410201B2 (en) 2012-12-14 2016-08-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US9662385B2 (en) 2008-06-27 2017-05-30 Zoetis Services Llc Adjuvant compositions
US9689024B2 (en) 2012-08-14 2017-06-27 10X Genomics, Inc. Methods for droplet-based sample preparation
US9694361B2 (en) 2014-04-10 2017-07-04 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9801842B2 (en) 2007-05-02 2017-10-31 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9821024B2 (en) 2010-11-25 2017-11-21 Sigmoid Pharma Limited Immunomodulatory compositions
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
USRE46906E1 (en) 2009-12-03 2018-06-26 Novartis Ag Methods for producing vaccine adjuvants
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
CN108721614A (zh) * 2018-06-12 2018-11-02 福建省农业科学院畜牧兽医研究所 兔葡萄球菌病、波氏杆菌病二联组织灭活疫苗及制备方法
US10117921B2 (en) 2013-09-19 2018-11-06 Zoetis Services Llc Oil-based adjuvants
US10143738B2 (en) * 2014-09-12 2018-12-04 Intervet Inc. Vaccine for use in protecting a pig against porcine epidemic diarrhea virus
US10213383B2 (en) 2009-12-03 2019-02-26 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10251950B2 (en) * 2014-07-11 2019-04-09 Zoetis Services Llc Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20190209676A1 (en) * 2016-08-17 2019-07-11 Nippon Institute For Biological Science Porcine Epidemic Diarrhea Preventative or Therapeutic Method, Vaccine, and Vaccine Kit
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10434138B2 (en) 2013-11-08 2019-10-08 Sublimity Therapeutics Limited Formulations
US10478487B2 (en) 2015-01-16 2019-11-19 Zoetis Services Llc Foot-and-mouth disease vaccine
CN110665002A (zh) * 2019-10-29 2020-01-10 信阳市动物疫病预防控制中心 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法
US10532019B2 (en) 2005-12-01 2020-01-14 University Of Massachusetts Lowell Botulinum nanoemulsions
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10588914B2 (en) 2009-08-31 2020-03-17 Encore Dermatology, Inc. Topical formulations comprising a steroid
US10650912B2 (en) 2015-01-13 2020-05-12 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US10839939B2 (en) 2014-06-26 2020-11-17 10X Genomics, Inc. Processes and systems for nucleic acid sequence assembly
US10854315B2 (en) 2015-02-09 2020-12-01 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin
US11058763B2 (en) 2015-02-27 2021-07-13 Zoetis Services Llc Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom
US11081208B2 (en) 2016-02-11 2021-08-03 10X Genomics, Inc. Systems, methods, and media for de novo assembly of whole genome sequence data
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
US11179465B2 (en) 2014-03-11 2021-11-23 Primus Pharmaceuticals, Inc. Topical compositions comprising a corticosteroid
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
CN114569715A (zh) * 2022-05-07 2022-06-03 中义(北京)健康研究院 疫苗组合物、疫苗佐剂及其制备方法和制备系统
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
WO2023056117A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic combination of alum and non-liposome, non-micelle particle vaccine adjuvants
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11717563B2 (en) 2008-06-05 2023-08-08 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11898206B2 (en) 2017-05-19 2024-02-13 10X Genomics, Inc. Systems and methods for clonotype screening

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
GB0319500D0 (en) 2003-08-19 2003-09-17 Resolution Chemicals Ltd Particle-size reduction apparatus,and use thereof
ES2409782T3 (es) 2004-04-05 2013-06-27 Zoetis P Llc Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna
FR2878746B1 (fr) * 2004-12-02 2007-02-23 Vetoquinol Sa Sa Nouvelle composition pharmaceutique utilisable dans le domaine des vaccins
GB0427568D0 (en) 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
RU2440137C1 (ru) * 2007-12-21 2012-01-20 Пфайзер Инк. Термообработанные бактерины и эмульсионные вакцины, полученные из таких термообработанных бактеринов
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
FR2957803B1 (fr) * 2010-03-24 2012-06-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Diluants adjuvants de vaccins vivants pour maladies porcines
CN101829323A (zh) * 2010-04-28 2010-09-15 洛阳普莱柯生物工程有限公司 一种禽用油乳剂疫苗及其制备方法
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
CN101926995B (zh) * 2010-08-19 2013-05-29 中国医学科学院医学生物学研究所 一种天冬免疫佐剂及含有该佐剂的流感疫苗
CN101926994B (zh) * 2010-08-19 2012-10-10 中国医学科学院医学生物学研究所 一种鳖甲免疫佐剂及含有该佐剂的流感疫苗
CN101978948A (zh) * 2010-11-02 2011-02-23 扬州威克生物工程有限公司 兽用油乳剂灭活疫苗的低温乳化工艺方法
CA2845872C (en) 2011-08-22 2023-03-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
US11000046B2 (en) 2012-12-27 2021-05-11 Jean-Claude Method for manufacturing an oil-in-water emulsion from an oily active substance, for cosmetic, food, or pharmaceutical use
KR20230039766A (ko) * 2017-12-20 2023-03-21 조에티스 서비시즈 엘엘씨 Hendra 및 Nipah 바이러스 감염을 대비한 백신
CN108159414B (zh) * 2018-01-15 2021-07-27 四川诺顺科技有限公司 动物疫苗用油包水佐剂及其制备方法和用途
US11786592B2 (en) * 2021-05-19 2023-10-17 The University Of Hong Kong Compositions of cardiolipin adjuvants and methods of use thereof

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4505900A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4908154A (en) * 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5585103A (en) * 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5804199A (en) * 1993-07-26 1998-09-08 Akzo Nobel N. V. Oil-based and water-based adjuvant mixture
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US6274149B1 (en) * 1995-04-20 2001-08-14 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6299884B1 (en) * 1989-05-25 2001-10-09 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US6306405B1 (en) * 1997-12-16 2001-10-23 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US6372227B1 (en) * 1997-09-05 2002-04-16 Smithkline Beecham Biologicals, S.A. Vaccines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1280739C (en) 1985-09-19 1991-02-26 Tatsuo Kinoshita Oil-in-water emulsion and use thereof as metal processing oil or the like
US4806350A (en) 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
ES2097840T3 (es) * 1987-11-03 1997-04-16 Syntex Inc Adyuvante de vacuna que comprende un tetrapoliol.
EP0626850B1 (en) 1992-02-18 2002-05-15 Pharmos Corporation Dry compositions for preparing submicron emulsions
WO1993024147A1 (en) * 1992-05-29 1993-12-09 Smithkline Beecham Corporation Lecithin adjuvanted modified live virus vaccines
RU2058154C1 (ru) * 1992-12-21 1996-04-20 Всероссийский научно-исследовательский институт защиты животных Адъювант
JPH0731413A (ja) 1993-07-14 1995-02-03 Ajinomoto Co Inc 広域温度安定性乳化組成物
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69807281T2 (de) 1997-05-14 2003-04-17 Senju Pharma Co Difluprednat enthaltende Zusammensetzungen
SE9702776D0 (sv) * 1997-07-22 1997-07-22 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions
US6682745B1 (en) * 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
ES2201551T3 (es) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
JP2002193790A (ja) 2000-12-27 2002-07-10 Lion Corp 水難溶性薬剤含有水中油型エマルジョン及びその製造方法

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4908154A (en) * 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US4505900A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US6299884B1 (en) * 1989-05-25 2001-10-09 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US6451325B1 (en) * 1989-05-25 2002-09-17 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5585103A (en) * 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
US5804199A (en) * 1993-07-26 1998-09-08 Akzo Nobel N. V. Oil-based and water-based adjuvant mixture
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US6274149B1 (en) * 1995-04-20 2001-08-14 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US6372227B1 (en) * 1997-09-05 2002-04-16 Smithkline Beecham Biologicals, S.A. Vaccines
US6306405B1 (en) * 1997-12-16 2001-10-23 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions

Cited By (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US8771731B2 (en) 1999-04-28 2014-07-08 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US20040043041A1 (en) * 1999-04-28 2004-03-04 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US8628937B2 (en) 2000-11-07 2014-01-14 Immunovaccine Technologies, Inc. Vaccines with enhanced immune response and methods for their preparation
US20090092666A1 (en) * 2000-11-07 2009-04-09 Immunovaccine Technologies, Inc. Vaccines with enhanced immune response and methods for their preparation
US9114174B2 (en) 2000-11-07 2015-08-25 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
US7824686B2 (en) 2000-11-07 2010-11-02 Immunovaccine Technologies, Inc. Vaccines with enhanced immune response and methods for their preparation
US20050019339A1 (en) * 2000-11-07 2005-01-27 Brown Robert George Vaccines with enhanced immune response and methods for their preparation
US8703164B2 (en) 2003-06-04 2014-04-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US9131680B2 (en) 2003-06-04 2015-09-15 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US20080020018A1 (en) * 2004-09-27 2008-01-24 Joey Moodley Combination Products
US20080113031A1 (en) * 2004-09-27 2008-05-15 Joey Moodley Minicapsule Formulations
US20070054834A1 (en) * 2005-04-11 2007-03-08 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
US20150335574A1 (en) * 2005-07-18 2015-11-26 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US10016364B2 (en) * 2005-07-18 2018-07-10 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US20110200657A1 (en) * 2005-08-09 2011-08-18 Nanobio Corporation Methods of using nanoemulsion compositions having anti-inflammatory activity
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US10532019B2 (en) 2005-12-01 2020-01-14 University Of Massachusetts Lowell Botulinum nanoemulsions
US10576034B2 (en) 2005-12-01 2020-03-03 University Of Massachusetts Lowell Botulinum nanoemulsions
US20080112970A1 (en) * 2006-09-11 2008-05-15 Pfizer Inc. Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
AU2007297287B2 (en) * 2006-09-11 2013-03-14 Zoetis Services Llc Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
US8491915B2 (en) * 2006-09-11 2013-07-23 Ah Usa 42 Llc Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
US10434139B2 (en) 2007-04-04 2019-10-08 Sublimity Therapeutics Limited Oral pharmaceutical composition
US9387179B2 (en) 2007-04-04 2016-07-12 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US9585844B2 (en) 2007-04-04 2017-03-07 Sigmoid Pharma Limited Oral pharmaceutical composition
US8535713B2 (en) 2007-04-04 2013-09-17 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US9675558B2 (en) 2007-04-04 2017-06-13 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US10434140B2 (en) 2007-04-04 2019-10-08 Sublimity Therapeutics Limited Pharmaceutical cyclosporin compositions
US9114071B2 (en) 2007-04-04 2015-08-25 Sigmoid Pharma Limited Oral pharmaceutical composition
US20100255087A1 (en) * 2007-04-04 2010-10-07 Ivan Coulter oral pharmaceutical composition
US20100203120A1 (en) * 2007-04-04 2010-08-12 Ivan Coulter Pharmaceutical cyclosporin compositions
US9801842B2 (en) 2007-05-02 2017-10-31 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US11235069B2 (en) 2007-09-27 2022-02-01 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US10232052B2 (en) 2007-09-27 2019-03-19 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US11717563B2 (en) 2008-06-05 2023-08-08 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US10238736B2 (en) 2008-06-27 2019-03-26 Zoetis Services Llc Adjuvant compositions
US9662385B2 (en) 2008-06-27 2017-05-30 Zoetis Services Llc Adjuvant compositions
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
US9999651B2 (en) 2009-05-18 2018-06-19 Sigmoid Pharma Limited Composition comprising oil drops
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
WO2011018504A3 (en) * 2009-08-12 2011-06-23 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
CN102573802A (zh) * 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
GB2485327A (en) * 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
US10905697B2 (en) 2009-08-31 2021-02-02 Encore Dermatology, Inc. Topical formulations comprising a steroid
US10588914B2 (en) 2009-08-31 2020-03-17 Encore Dermatology, Inc. Topical formulations comprising a steroid
US10213383B2 (en) 2009-12-03 2019-02-26 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
US20110165193A1 (en) * 2009-12-03 2011-07-07 Novartis Vaccines and Diagnostics, GmbH & Co. KG Methods for producing vaccine adjuvants
US10799454B2 (en) 2009-12-03 2020-10-13 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
WO2011067672A3 (en) * 2009-12-03 2011-12-01 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EA031593B1 (ru) * 2009-12-03 2019-01-31 Новартис Аг Способ получения эмульсии масло-в-воде
US8895629B2 (en) 2009-12-03 2014-11-25 Novartis Ag Circulation of components during homogenization of emulsions
EP2380558A1 (en) * 2009-12-03 2011-10-26 Novartis AG Arranging interaction and back pressure chambers for microfluidization
US9700616B2 (en) 2009-12-03 2017-07-11 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
US10463615B2 (en) 2009-12-03 2019-11-05 Novartis Ag Circulation of components during microfluidization and/or homogenization of emulsions
US9750690B2 (en) 2009-12-03 2017-09-05 Novartis Ag Circulation of components during microfluidization and/or homogenization of emulsions
US9463240B2 (en) 2009-12-03 2016-10-11 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
DE102009056883A1 (de) * 2009-12-03 2011-06-09 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2380558B2 (en) † 2009-12-03 2019-10-16 Novartis AG Manufacturing of an emulsion under arrangement of interaction and back pressure chamber for microfluidization
US20110165192A1 (en) * 2009-12-03 2011-07-07 Novartis Vaccines and Diagnostics, GmbH & Co. KG Methods for producing vaccine adjuvants
US8678184B2 (en) 2009-12-03 2014-03-25 Novartis Ag Methods for producing vaccine adjuvants
US20110162982A1 (en) * 2009-12-03 2011-07-07 Novartis Vaccines and Diagnostic, GmbH & Co. KG Methods for producing vaccine adjuvants
US8778275B2 (en) 2009-12-03 2014-07-15 Novartis Ag Methods for producing vaccine adjuvants
USRE46441E1 (en) 2009-12-03 2017-06-20 Novartis Ag Circulation of components during homogenization of emulsions
US8871816B2 (en) 2009-12-03 2014-10-28 Novartis Ag Methods for producing vaccine adjuvants
USRE46906E1 (en) 2009-12-03 2018-06-26 Novartis Ag Methods for producing vaccine adjuvants
US11141376B2 (en) 2009-12-03 2021-10-12 Novartis Ag Circulation of components during microfluidization and/or homogenization of emulsions
US9821024B2 (en) 2010-11-25 2017-11-21 Sigmoid Pharma Limited Immunomodulatory compositions
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
US11077184B2 (en) 2011-10-06 2021-08-03 Immunovaccine Technologies Inc. Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response
US9950051B2 (en) 2012-07-05 2018-04-24 Sigmoid Pharma Limited Formulations
US9220681B2 (en) 2012-07-05 2015-12-29 Sigmoid Pharma Limited Formulations
US11359239B2 (en) 2012-08-14 2022-06-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11021749B2 (en) 2012-08-14 2021-06-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752950B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11035002B2 (en) 2012-08-14 2021-06-15 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10669583B2 (en) 2012-08-14 2020-06-02 10X Genomics, Inc. Method and systems for processing polynucleotides
US11078522B2 (en) 2012-08-14 2021-08-03 10X Genomics, Inc. Capsule array devices and methods of use
US10626458B2 (en) 2012-08-14 2020-04-21 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10597718B2 (en) 2012-08-14 2020-03-24 10X Genomics, Inc. Methods and systems for sample processing polynucleotides
US10053723B2 (en) 2012-08-14 2018-08-21 10X Genomics, Inc. Capsule array devices and methods of use
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9689024B2 (en) 2012-08-14 2017-06-27 10X Genomics, Inc. Methods for droplet-based sample preparation
US9695468B2 (en) 2012-08-14 2017-07-04 10X Genomics, Inc. Methods for droplet-based sample preparation
US10450607B2 (en) 2012-08-14 2019-10-22 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11441179B2 (en) 2012-08-14 2022-09-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10253364B2 (en) 2012-12-14 2019-04-09 10X Genomics, Inc. Method and systems for processing polynucleotides
US9567631B2 (en) 2012-12-14 2017-02-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11473138B2 (en) 2012-12-14 2022-10-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10612090B2 (en) 2012-12-14 2020-04-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9410201B2 (en) 2012-12-14 2016-08-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9856530B2 (en) 2012-12-14 2018-01-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11421274B2 (en) 2012-12-14 2022-08-23 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10150964B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10150963B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US11193121B2 (en) 2013-02-08 2021-12-07 10X Genomics, Inc. Partitioning and processing of analytes and other species
US9644204B2 (en) * 2013-02-08 2017-05-09 10X Genomics, Inc. Partitioning and processing of analytes and other species
US9388465B2 (en) 2013-02-08 2016-07-12 10X Genomics, Inc. Polynucleotide barcode generation
US20140227684A1 (en) * 2013-02-08 2014-08-14 10X Technologies, Inc. Partitioning and processing of analytes and other species
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
US11701415B2 (en) 2013-09-19 2023-07-18 Zoetis Services Llc Oil-based adjuvants
US10117921B2 (en) 2013-09-19 2018-11-06 Zoetis Services Llc Oil-based adjuvants
US10953080B2 (en) 2013-09-19 2021-03-23 Zoetis Services Llc Oil-based adjuvants
US10434138B2 (en) 2013-11-08 2019-10-08 Sublimity Therapeutics Limited Formulations
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
US11179465B2 (en) 2014-03-11 2021-11-23 Primus Pharmaceuticals, Inc. Topical compositions comprising a corticosteroid
US10343166B2 (en) 2014-04-10 2019-07-09 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10137449B2 (en) 2014-04-10 2018-11-27 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9694361B2 (en) 2014-04-10 2017-07-04 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10150117B2 (en) 2014-04-10 2018-12-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10071377B2 (en) 2014-04-10 2018-09-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US11713457B2 (en) 2014-06-26 2023-08-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10208343B2 (en) 2014-06-26 2019-02-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10030267B2 (en) 2014-06-26 2018-07-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10457986B2 (en) 2014-06-26 2019-10-29 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10839939B2 (en) 2014-06-26 2020-11-17 10X Genomics, Inc. Processes and systems for nucleic acid sequence assembly
US10337061B2 (en) 2014-06-26 2019-07-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11133084B2 (en) 2014-06-26 2021-09-28 10X Genomics, Inc. Systems and methods for nucleic acid sequence assembly
US10041116B2 (en) 2014-06-26 2018-08-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480028B2 (en) 2014-06-26 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10760124B2 (en) 2014-06-26 2020-09-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10344329B2 (en) 2014-06-26 2019-07-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10953088B2 (en) * 2014-07-11 2021-03-23 Zoetis Services Llc Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
US10251950B2 (en) * 2014-07-11 2019-04-09 Zoetis Services Llc Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
US20190216919A1 (en) * 2014-07-11 2019-07-18 Zoetis Services Llc Novel Vaccine Compositions for Porcine Epidemic Diarrhea Virus and Porcine Deltacoronavirus
US10143738B2 (en) * 2014-09-12 2018-12-04 Intervet Inc. Vaccine for use in protecting a pig against porcine epidemic diarrhea virus
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US11739368B2 (en) 2014-10-29 2023-08-29 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10245587B2 (en) 2014-11-05 2019-04-02 10X Genomics, Inc. Instrument systems for integrated sample processing
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
US10993987B2 (en) 2014-11-07 2021-05-04 Sublimity Therapeutics Limited Compositions comprising Cyclosporin
US10557158B2 (en) 2015-01-12 2020-02-11 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US11414688B2 (en) 2015-01-12 2022-08-16 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10650912B2 (en) 2015-01-13 2020-05-12 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US10478487B2 (en) 2015-01-16 2019-11-19 Zoetis Services Llc Foot-and-mouth disease vaccine
US10854315B2 (en) 2015-02-09 2020-12-01 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
US11603554B2 (en) 2015-02-24 2023-03-14 10X Genomics, Inc. Partition processing methods and systems
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US11058763B2 (en) 2015-02-27 2021-07-13 Zoetis Services Llc Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom
US11473125B2 (en) 2015-12-04 2022-10-18 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11873528B2 (en) 2015-12-04 2024-01-16 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11624085B2 (en) 2015-12-04 2023-04-11 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11081208B2 (en) 2016-02-11 2021-08-03 10X Genomics, Inc. Systems, methods, and media for de novo assembly of whole genome sequence data
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US20190209676A1 (en) * 2016-08-17 2019-07-11 Nippon Institute For Biological Science Porcine Epidemic Diarrhea Preventative or Therapeutic Method, Vaccine, and Vaccine Kit
US11013797B2 (en) * 2016-08-17 2021-05-25 Nippon Institute For Biological Science Porcine epidemic diarrhea preventative or therapeutic method, vaccine, and vaccine kit
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US10793905B2 (en) 2016-12-22 2020-10-06 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10858702B2 (en) 2016-12-22 2020-12-08 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480029B2 (en) 2016-12-22 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11180805B2 (en) 2016-12-22 2021-11-23 10X Genomics, Inc Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323278B2 (en) 2016-12-22 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11193122B2 (en) 2017-01-30 2021-12-07 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US11898206B2 (en) 2017-05-19 2024-02-13 10X Genomics, Inc. Systems and methods for clonotype screening
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11155810B2 (en) 2017-05-26 2021-10-26 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10927370B2 (en) 2017-05-26 2021-02-23 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11198866B2 (en) 2017-05-26 2021-12-14 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10876147B2 (en) 2017-11-15 2020-12-29 10X Genomics, Inc. Functionalized gel beads
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US11884962B2 (en) 2017-11-15 2024-01-30 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
CN108721614A (zh) * 2018-06-12 2018-11-02 福建省农业科学院畜牧兽医研究所 兔葡萄球菌病、波氏杆菌病二联组织灭活疫苗及制备方法
CN110665002A (zh) * 2019-10-29 2020-01-10 信阳市动物疫病预防控制中心 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法
WO2023056117A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic combination of alum and non-liposome, non-micelle particle vaccine adjuvants
CN114569715A (zh) * 2022-05-07 2022-06-03 中义(北京)健康研究院 疫苗组合物、疫苗佐剂及其制备方法和制备系统

Also Published As

Publication number Publication date
BRPI0408635B1 (pt) 2019-07-16
KR20060006909A (ko) 2006-01-20
BRPI0408635A (pt) 2006-03-28
EP1613346A2 (en) 2006-01-11
CY1113546T1 (el) 2016-06-22
UY28256A1 (es) 2004-11-30
NO20054376L (no) 2006-01-03
US8771727B2 (en) 2014-07-08
TW200509966A (en) 2005-03-16
HK1086484A1 (en) 2006-09-22
WO2004087204A2 (en) 2004-10-14
RU2541809C2 (ru) 2015-02-20
AR043803A1 (es) 2005-08-10
NO20054376D0 (no) 2005-09-21
DK1613346T3 (da) 2013-01-07
CA2521051A1 (en) 2004-10-14
CN1767854A (zh) 2006-05-03
KR100720213B1 (ko) 2007-05-21
RU2005130646A (ru) 2006-01-27
PT1613346E (pt) 2013-01-29
CN1767854B (zh) 2013-07-24
US20100173854A1 (en) 2010-07-08
WO2004087204A3 (en) 2004-12-23
MXPA05010697A (es) 2005-12-12
ZA200507994B (en) 2007-03-28
SI1613346T1 (sl) 2013-02-28
AU2004226591A1 (en) 2004-10-14
NZ542576A (en) 2008-11-28
RU2009113834A (ru) 2010-10-20
PL1613346T3 (pl) 2013-03-29
EP1613346B1 (en) 2012-11-28
JP2006522090A (ja) 2006-09-28
TWI353850B (en) 2011-12-11
EP1613346B8 (en) 2013-01-09
CA2521051C (en) 2012-03-20
AU2004226591B2 (en) 2009-06-04
CL2004000691A1 (es) 2005-05-06
ES2398235T3 (es) 2013-03-14

Similar Documents

Publication Publication Date Title
US8771727B2 (en) Microfluidized oil-in-water emulsions and vaccine compositions
US7122191B2 (en) Microfluidized oil-in-water emulsions and vaccine compositions
JP2022001581A (ja) 油性アジュバント
MXPA06011569A (en) Microfluidized oil-in-water emulsions and vaccine compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: PFIZER PRODUCTS, INC., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOMINOWSKI, PAUL J.;KLOSE, PAMELA;KREBS, RICHARD L.;AND OTHERS;REEL/FRAME:015738/0224;SIGNING DATES FROM 20040805 TO 20040813

Owner name: PFIZER INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOMINOWSKI, PAUL J.;KLOSE, PAMELA;KREBS, RICHARD L.;AND OTHERS;REEL/FRAME:015738/0224;SIGNING DATES FROM 20040805 TO 20040813

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PFIZER INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PFIZER PRODUCTS INC.;REEL/FRAME:029041/0099

Effective date: 20120928

AS Assignment

Owner name: AH USA 42 LLC, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PFIZER INC.;REEL/FRAME:029596/0001

Effective date: 20121001

AS Assignment

Owner name: PFIZER INC., NEW YORK

Free format text: CORRECTION BY DECLARATION OF INCORRECT NUMBERS RECORDED AT REEL 029041 FRAME 0099;ASSIGNOR:PFIZER INC.;REEL/FRAME:029926/0644

Effective date: 20130131

AS Assignment

Owner name: PFIZER INC., NEW YORK

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 015738 FRAME 0224. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:DOMINOWSKI, PAUL J.;KLOSE, PAMELA;KREBS, RICHARD L.;AND OTHERS;SIGNING DATES FROM 20040805 TO 20040813;REEL/FRAME:030221/0948